277 related articles for article (PubMed ID: 33178839)
1. Genetic Mutations of Tim-3 Ligand and Exhausted Tim-3
Zhang T; Ren T; Song Z; Zhao J; Jiao L; Zhang Z; He J; Liu X; Qiu L; Li L; Zhou S; Meng B; Zhai Q; Ren X; Qian Z; Wang X; Zhang H
J Immunol Res; 2020; 2020():6968595. PubMed ID: 33178839
[TBL] [Abstract][Full Text] [Related]
2. Diffuse large B-cell lymphoma: the significance of CD8
Zhu Q; Yang Y; Chen K; Zhang Q; Huang Y; Jian S
J Transl Med; 2024 Feb; 22(1):174. PubMed ID: 38369502
[TBL] [Abstract][Full Text] [Related]
3. Oncolytic adenovirus decreases the proportion of TIM-3
Liikanen I; Basnet S; Quixabeira DCA; Taipale K; Hemminki O; Oksanen M; Kankainen M; Juhila J; Kanerva A; Joensuu T; Tähtinen S; Hemminki A
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35193929
[TBL] [Abstract][Full Text] [Related]
4. Tumor CD73/A2aR adenosine immunosuppressive axis and tumor-infiltrating lymphocytes in diffuse large B-cell lymphoma: correlations with clinicopathological characteristics and clinical outcome.
Wang X; Zhang T; Song Z; Li L; Zhang X; Liu J; Liu X; Qiu L; Qian Z; Zhou S; Feng L; Hu G; Meng B; Zhai Q; Ren X; Fu K; Li L; Wang P; Zhang H
Int J Cancer; 2019 Sep; 145(5):1414-1422. PubMed ID: 30664812
[TBL] [Abstract][Full Text] [Related]
5. Characterization of TIM-3 expression and its prognostic value in patients with surgically resected lung adenocarcinoma.
Su H; Xie H; Dai C; Ren Y; She Y; Xu L; Chen D; Xie D; Zhang L; Jiang G; Chen C
Lung Cancer; 2018 Jul; 121():18-24. PubMed ID: 29858021
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of PD-1 and TIM-3 on CD3+ T cells from diffuse large B-cell lymphoma.
Zhang L; Du H; Xiao TW; Liu JZ; Liu GZ; Wang JX; Li GY; Wang LX
Biomed Pharmacother; 2015 Oct; 75():83-7. PubMed ID: 26463635
[TBL] [Abstract][Full Text] [Related]
7. Blocking Tim-3 or/and PD-1 reverses dysfunction of tumor-infiltrating lymphocytes in HBV-related hepatocellular carcinoma.
Liu F; Zeng G; Zhou S; He X; Sun N; Zhu X; Hu A
Bull Cancer; 2018 May; 105(5):493-501. PubMed ID: 29576222
[TBL] [Abstract][Full Text] [Related]
8. Low Distribution of TIM-3
Zhuang C; Ni B; Zhang ZZ; Zhao WY; Tu L; Ma XL; Yang LX; Cao H; Wang M
J Immunol Res; 2021; 2021():6647292. PubMed ID: 33681387
[TBL] [Abstract][Full Text] [Related]
9. High levels of Tim-3
Zhong W; Liu X; Zhu Z; Li Q; Li K
Int Immunopharmacol; 2021 Jul; 96():107662. PubMed ID: 33864956
[TBL] [Abstract][Full Text] [Related]
10. Tim-3 expression is increased on peripheral T cells from diffuse large B cell lymphoma.
Xiao T; Zhang L; Chen L; Liu G; Feng Z; Gao L
Tumour Biol; 2014 Aug; 35(8):7951-6. PubMed ID: 24833097
[TBL] [Abstract][Full Text] [Related]
11. Adverse prognostic impact of regulatory T-cells in testicular diffuse large B-cell lymphoma.
Pollari M; Pellinen T; Karjalainen-Lindsberg ML; Kellokumpu-Lehtinen PL; Leivonen SK; Leppä S
Eur J Haematol; 2020 Dec; 105(6):712-721. PubMed ID: 32632935
[TBL] [Abstract][Full Text] [Related]
12. MiRNA-340-5p mediates the functional and infiltrative promotion of tumor-infiltrating CD8
Xu Y; Liu Z; Lv L; Li P; Xiu B; Qian W; Liang A
J Exp Clin Cancer Res; 2020 Nov; 39(1):238. PubMed ID: 33168024
[TBL] [Abstract][Full Text] [Related]
13. Implications of infiltrating immune cells within bone marrow of patients with diffuse large B-cell lymphoma.
Jeong J; Oh EJ; Yang WI; Kim SJ; Yoon SO
Hum Pathol; 2017 Jun; 64():222-231. PubMed ID: 28438619
[TBL] [Abstract][Full Text] [Related]
14. TIM-3 Dictates Functional Orientation of the Immune Infiltrate in Ovarian Cancer.
Fucikova J; Rakova J; Hensler M; Kasikova L; Belicova L; Hladikova K; Truxova I; Skapa P; Laco J; Pecen L; Praznovec I; Halaska MJ; Brtnicky T; Kodet R; Fialova A; Pineau J; Gey A; Tartour E; Ryska A; Galluzzi L; Spisek R
Clin Cancer Res; 2019 Aug; 25(15):4820-4831. PubMed ID: 31076549
[TBL] [Abstract][Full Text] [Related]
15. Targeting PD-1 and Tim-3 Pathways to Reverse CD8 T-Cell Exhaustion and Enhance Ex Vivo T-Cell Responses to Autologous Dendritic/Tumor Vaccines.
Liu J; Zhang S; Hu Y; Yang Z; Li J; Liu X; Deng L; Wang Y; Zhang X; Jiang T; Lu X
J Immunother; 2016 May; 39(4):171-80. PubMed ID: 27070448
[TBL] [Abstract][Full Text] [Related]
16. Characterisation of tumour microenvironment and immune checkpoints in primary central nervous system diffuse large B cell lymphomas.
Alame M; Pirel M; Costes-Martineau V; Bauchet L; Fabbro M; Tourneret A; De Oliveira L; Durand L; Roger P; Gonzalez S; Cacheux V; Rigau V; Szablewski V
Virchows Arch; 2020 Jun; 476(6):891-902. PubMed ID: 31811434
[TBL] [Abstract][Full Text] [Related]
17. Blockade of PD-1 and TIM-3 immune checkpoints fails to restore the function of exhausted CD8
Rezazadeh H; Astaneh M; Tehrani M; Hossein-Nataj H; Zaboli E; Shekarriz R; Asgarian-Omran H
Immunol Res; 2020 Oct; 68(5):269-279. PubMed ID: 32710227
[TBL] [Abstract][Full Text] [Related]
18. TIM-3 expression characterizes regulatory T cells in tumor tissues and is associated with lung cancer progression.
Gao X; Zhu Y; Li G; Huang H; Zhang G; Wang F; Sun J; Yang Q; Zhang X; Lu B
PLoS One; 2012; 7(2):e30676. PubMed ID: 22363469
[TBL] [Abstract][Full Text] [Related]
19. Presence of Tim3
Klapholz M; Drage MG; Srivastava A; Anderson AC
J Pathol; 2022 Jun; 257(2):186-197. PubMed ID: 35119692
[TBL] [Abstract][Full Text] [Related]
20. Functional characterization of PD1+TIM3+ tumor-infiltrating T cells in DLBCL and effects of PD1 or TIM3 blockade.
Roussel M; Le KS; Granier C; Llamas Gutierrez F; Foucher E; Le Gallou S; Pangault C; Xerri L; Launay V; Lamy T; Tartour E; Olive D; Fest T
Blood Adv; 2021 Apr; 5(7):1816-1829. PubMed ID: 33787861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]